Clinical trials: Cerebrovascular Circulation
Gait or Balance Disorder Problems
The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow
Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic…
- Trial name
- CBF (NCT01468285)
- Testing
- betahistine dihydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 27 people
- Sponsor
- Abbott Products
Ischemic Stricture of Intestine
Safety and Effectiveness Evaluation of the ISS System in Treatment of Acute Ischemic Stroke
The primary objective of this pilot study is the assessment of the safety of the ISS500 System in patients who have experienced an acute ischemic stroke within the anterior circulation.
- Trial name
- ImpACT-1 (NCT03733236)
- Testing
- ISS Active Stimulation
- Where
- 2 sites in India
- Volunteers
- 98 people
- Sponsor
- BrainsGate
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Pain, Low Back Pain
Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain
The primary objective of this study is to identify the brain regions in which activity is affected by SCS. Baseline cerebral blood flow scans with the device turned off will be generated compared to scans produced with the device…
- Conditions
- Pain, Low Back Pain, Leg Pain
- Trial name
- NCT00418301
- Testing
- Precision Spinal Cord Stimulation and PET Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ischemic Stroke
Glyburide Advantage in Malignant Edema and Stroke Pilot
The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard…
- Trial name
- GAMES-PILOT (NCT01268683)
- Testing
- Glyburide for Injection
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Stroke, Ischemic, Infarction, Middle Cerebral Artery
Testing of Identification Markers for Stroke
Stroke is the third leading cause of death and the first cause of physical disability and dementia worldwide. Ischemic stroke caused by large vessel occlusion (LVO) is responsible for the vast majority of deaths and disabilities.
- Conditions
- Stroke, Ischemic, Infarction, Middle Cerebral Artery, Infarction, Anterior Circulation, Brain
- Trial name
- TIME (NCT04292600)
- Testing
- POCKiT diagnostics' algorithm for LVO detection
- Where
- 3 sites in United States
- Volunteers
- 383 people
- Sponsor
- POCKiT diagnostics Ltd
Ischemic Stroke
THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset)
Study Population: Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from onset. Study objectives: 1. Identify the personal stimulation level for each patient based on physiological biomarkers 2.
- Trial name
- ImpACT-24M (NCT03551093)
- Testing
- ISS SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 50 people
- Sponsor
- BrainsGate
Heart Failure With Reduced Ejection Fraction
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes.
- Trial name
- LYRIC-HF (NCT07695090)
- Testing
- Lumacaftor 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Qanatpharma AG
Ischemic Stroke
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
The purpose of the ImpACT-24col sub-study is to explore effect of SPG stimulation on the augmentation of collateral blood flow and to relate it to the subject's cerebral blood flow status, the extent of the collateral vessel…
- Trial name
- NCT03396419
- Where
- Georgia
- Volunteers
- 1 people
- Sponsor
- BrainsGate
Ischaemic Stroke
The RETRAIN Trial Phase 2
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom.
- Trial name
- RETRAIN 2 (NCT07197996)
- Testing
- Intermittent Pneumatic Compression, geko® T3
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- Firstkind Ltd
Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24B (NCT00826059)
- Testing
- Active Sphenopalatine Ganglion (SPG) Stimulation
- Where
- 73 sites in United States, Canada and 16 more
- Volunteers
- 1,078 people
- Sponsor
- BrainsGate
Ischemic Stroke
IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in the anterior circulation, who received Mechanical…
- Trial name
- IMPACT-24Bt (NCT01874093)
- Testing
- The Ischemic Stroke System
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- BrainsGate
Ischemic Stroke
Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
- Trial name
- ImpACT-P (NCT04014621)
- Testing
- SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 100 people
- Sponsor
- BrainsGate
Normal Subject / Healthy Volunteers
VitalFlow Healthy Volunteer Study
Find the stimulation threshold of the facial nerve (ganglion Geniculate) associated with tolerability and safety in subjects Healthy humans.
- Trial name
- NCT03487393
- Testing
- magnetic facial nerve stimulation
- Where
- Mexico
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Nervive, Inc.
Ischemic Stroke, Malignant Edema
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation…
- Trial name
- GAMES-RP (NCT01794182)
- Testing
- Glyburide for Injection
- Where
- 17 sites in United States
- Volunteers
- 86 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Reconstructive Surgical Procedures, Plastic Surgery
Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.
This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW800 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope.
- Conditions
- Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder
- Trial name
- IMED-GLOW800 (NCT07164040)
- Testing
- The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG
- Where
- 3 sites in Portugal, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Leica Microsystems (Schweiz) AG
Cerebrovascular Circulation
Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.
The current study would investigate the effects of a single dose of darolutamide and enzalutamide compared with placebo and compared to each other on human brain blood flow using arterial spin labeling magnetic resonance imaging…
- Trial name
- NCT03704519
- Testing
- Darolutamide (BAY1841788), Enzalutamide
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bayer
Traumatic Brain Injury
Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players
The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL…
- Trial name
- NCT01515839
- Testing
- Multivitamin Supplement intervention
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amen Clinics, Inc.
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic